Insights & Analysis

Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

Page 27

Activism

Activist Investing Today: Goldstein Targets Fund Bylaws

By Ronald Orol
|
Published: May 7th, 2020
Activist investor Phil Goldstein of Bulldog Investors believes a recent SEC decision upholding closed-end fund Dividend & Income's right to ignore a shareholder proposal poses a broader threat to investor rights.
Activism

Activist Investing Today: Jackson Calls for eBay M&A

By Ronald Orol
|
Published: April 22nd, 2020
The manager of technology-focused hedge fund EMJ Capital says he thinks the company should use cash on hand — and proceeds from expected unit sales — to make its own acquisitions.
Activism

Activist Investing Today: Privet’s Rosenzweig on Synalloy, Covid-19

By Ronald Orol
|
Published: March 30th, 2020
The partner at the event-driven and value-oriented insurgent fund explains why he is plodding ahead with a change-of-control director contest at a metals and specialty company even though he is 'cognizant' of the coronavirus' effects on the world.
Activism

Activist Investing Today: Coast's Rasteh on FirstGroup, Covid-19

By Ronald Orol
|
Published: March 23rd, 2020
The founder of the New York-based activist fund explains why he's sticking with his investment and campaign at transport and school bus company FirstGroup — one of the fund's largest positions — even as its share price gets battered.
Activism

Activist Investing Today: V&E's Elbaum on Covid-19 vs. 2008

By Ronald Orol
|
Published: March 13th, 2020
The co-head of the shareholder activism practice at Vinson & Elkins explains what the 2008 financial crisis can teach us about how activists might react and perform during the coronavirus outbreak.
M&A

Drinks With The Deal: Ted Smith of Union Square Advisors

By David Marcus
|
Published: February 11th, 2020
Sullivan’s head of M&A talks to The Deal's David Marcus about his recent work for Tiffany’s, Novartis and Amgen, the challenges consumer goods companies face, and his favorite bars in Hong Kong, Tokyo and New York.